Corrigendum to 'The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148-1159]
Ann Oncol
.
2021 Aug;32(8):1066-1067.
doi: 10.1016/j.annonc.2021.05.796.
Epub 2021 Jun 2.
Authors
M R Mirza
1
,
R L Coleman
2
,
A González-Martín
3
,
K N Moore
4
,
N Colombo
5
,
I Ray-Coquard
6
,
S Pignata
7
Affiliations
1
Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address: Mansoor.Raza.Mirza@regionh.dk.
2
Department of Gynecologic Oncology & Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, USA.
3
Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain.
4
Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, USA.
5
Division of Medical Gynecologic Oncology, European Institute of Oncology IRCCS, University of Milan-Bicocca, Milan, Italy.
6
Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France.
7
Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G.Pascale, Napoli, Italy.
PMID:
34090767
DOI:
10.1016/j.annonc.2021.05.796
No abstract available
Publication types
Published Erratum